Treatment of recurrent Crohn's uveitis with infliximab

American Journal of Gastroenterology

Volumn 103, Issue 8, 2008, Pages 2150-2151

  Ally, Mazer R ^a,b   Veerappan, Ganesh R ^a,b   Koff, Jonathan M ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; STEROID;

AGED; CASE REPORT; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; EYE BURNING; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SLIT LAMP; UVEITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; UVEITIS;

EID: 49349093828     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01982_12.x     Document Type: Letter

References (26)

1. Juillerat P, Mottet C, Froehlich F, et al. Extraintestinal manifestations of Crohn's disease. Digestion 2005 71 : 31 6.
2. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007 13 : 1424 9.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 35.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 405.
5. Mintz R, Feller ER, Bahr RL, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004 10 : 135 9.
6. Barrie A, Plevy S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin North Am 2006 35 : 883 93.
7. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ 2000 320 : 555 8.
8. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994 118 : 601 11.
9. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: The involvement of HLA-B27. Curr Med Res Opin 2004 20 : 155 7.
10. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007 144 : 844 9.
11. Sharma SM, Ramanan AV, Riley P, et al. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease. Ann Rheum Dis 2007 66 : 840 1.
12. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007 125 : 895 900.
13. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006 113 : 2317 23.
14. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006 113 : 860 4.e2.
15. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006 113 : 308 14.
16. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006 45 : 982 9.
17. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005 43 : 7 11.
18. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab). Eye 2005 19 : 841 5.
19. Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005 89 : 533 6.
20. Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005 34 : 387 91.
21. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Arch Ophthalmol 2005 123 : 903 12.
22. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor- alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004 111 : 352 6.
23. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003 110 : 1449 53.
24. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002 109 : 2342 6.
25. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001 45 : 252 7.
26. Fries W, Giofre MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 2002 97 : 499 500.